Letters
DPP-4 inhibitors in type 2 diabetes
No better than less expensive drugs
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2914 (Published 24 April 2012) Cite this as: BMJ 2012;344:e2914- Thomas L Perry, clinical assistant professor 1,
- Stephen S Lippman, endocrinologist2,
- Mark McConnell, internist2,
- Aaron M Tejani, research associate1
- 1Therapeutics Initiative, University of British Columbia, BC, Vancouver, Canada, V6T 1Z3
- 2Veterans Administration, Sacramento, CA, USA
- tom.perry{at}ti.ubc.ca
The meta-analysis of short term studies using dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes indicates that they lower glycated haemoglobin (HbA1C) without causing weight gain or increasing mortality or serious adverse events. 1 In return, they increase drug costs.
However, drug treatment for type 2 diabetes aims to prevent or …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.